1 O'Connor JP,
Tofts PS,
Miles KA,
Parkes LM,
Thompson G,
Jackson A.
Dynamic contrast-enhanced imaging techniques: CT and MRI.
Br J Radiol.
2011;84 Spec No 2:S112-20.
2 Jiang J,
Xiao Z,
Tang Z,
Zhong Y,
Qiang J.
Differentiating between benign and malignant sinonasal lesions using dynamic contrast-enhanced MRI and intravoxel incoherent motion.
Eur J Radiol.
2018;98:7-13.
3 Zahra MA,
Hollingsworth KG,
Sala E,
Lomas DJ,
Tan LT.
Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy.
Lancet Oncol.
2007;8(1):63-74.
4 Huang W,
Beckett BR,
Tudorica A,
et al.
Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Tomography.
2016;2(4):308-316.
5 Ulyte A,
Katsaros VK,
Liouta E,
et al.
Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
Neuroradiology.
2016;58(12):1197-1208.
6 Tao X,
Wang L,
Hui Z,
et al.
DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC.
Sci Rep.
2016;6:35569.
7 Drisis S,
Metens T,
Ignatiadis M,
Stathopoulos K,
Chao SL,
Lemort M.
Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Eur Radiol.
2016;26(5):1474-84.
8 Pickles MD,
Lowry M,
Manton DJ,
Gibbs P,
Turnbull LW.
Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
Breast Cancer Res Treat.
2005;91(1):1-10.
9 Tudorica A,
Oh KY,
Chui SY,
et al.
Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI.
Transl Oncol.
2016;9(1):8-17.
10 Ng SH,
Liao CT,
Lin CY,
et al.
Dynamic contrast-enhanced MRI,
diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.
Eur Radiol.
2016;26(11):4162-4172.
11 Tong T,
Sun Y,
Gollub MJ,
et al.
Dynamic contrast-enhanced MRI: Use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer.
J Magn Reson Imaging.
2015;42(3):673-80.
12 Ng SH,
Lin CY,
Chan SC,
et al.
Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI,
diffusion-weighted MRI,
and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.
PLoS ONE.
2014;9(12):e115933.
13 Guo J,
Reddick WE,
Glass JO,
et al.
Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.
Cancer.
2012;118(15):3776-85.
14 Chang YC,
Yu CJ,
Chen CM,
et al.
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab,
gemcitabine,
and cisplatin.
J Magn Reson Imaging.
2012;36(2):387-96.
15 Jensen LR,
Garzon B,
Heldahl MG,
Bathen TF,
Lundgren S,
Gribbestad IS.
Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.
J Magn Reson Imaging.
2011;34(5):1099-109.
16 Leach MO,
Brindle KM,
Evelhoch JL,
et al.
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
Br J Cancer.
2005;92(9):1599-610.